PRESS RELEASE

NERVIANO MEDICAL SCIENCES

Nerviano Medical Sciences announces NMPA Clearance of IND for PARP7-Selective Inhibitor Atamparib in Promising New Therapeutic Setting

NERVIANO, Italy, BOSTON, Mass., SHANGHAI, China, 12 January 2026 – NMS Group (NMS), a global leader in oncological innovation, today announced that the China's National Medical Products Administration (NMPA) has granted approval to the Investigational New Drug (IND) application for its first-in-class, orally bioavailable PARP7-selective inhibitor, atamparib, enabling its clinical studies in patients with advanced solid tumors.

The phase Ib/II clinical trial expected to start in the first quarter of 2026 is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib in patients with advanced solid tumors, with a focus on a promising new therapeutic sub-setting. The goal is to validate the molecule's differentiated mechanism of action and its favorable safety and tolerability with more than 200 patients treated so far, both in late-line patients and in future combination with standard-of-care in earlier treatment settings.

"*The IND approval in China represents a key strategic milestone for the development of atamparib*," said Hugues Dolgos, CEO of NMS Srl. "*Recent data generated across preclinical and clinical programs, along with the newly published mechanism of action, have enabled us to reposition this asset into a promising sizeable indication where we believe it can deliver meaningful clinical benefit*."

"*Conducting the study in China is expected to support atamparib global clinical development by enabling timely access to a clinically relevant patient population and facilitating the potential availability of new treatment options for patients in China and worldwide*," said Dadong Li, CEO of NMS Shanghai. "*This milestone marks an important step in advancing the development of atamparib and exploring its potential to expand treatment options for patients*."

In parallel, NMS is advancing a dual inhibitor program currently in preclinical development, targeting PARP7 and another undisclosed target, which is expected to complement the clinical development strategy of atamparib and underscores the company's commitment to building a differentiated portfolio of innovative therapeutic candidates.

About Atamparib (PARP7 inhibitor)

Atamparib is a first-in-class, orally bioavailable, and selective PARP7 inhibitor acquired by NMS from Ribon Therapeutics in November 2024. It has demonstrated a favorable tolerability in prior clinical evaluation. Supported by new preclinical and clinical data, along with a scientific rationale supported by recent elucidations of its mechanism of action published by NMS advisor Prof. Michael Hottiger[1], NMS is advancing atamparib for the treatment of advanced or metastatic solid tumors, with the goal of addressing significant unmet medical needs.

PRESS RELEASE

NERVIANO MEDICAL SCIENCES

About NMS Group (NMS)

NMS is a global, integrated biopharmaceutical company focused on the discovery and development of innovative oncology therapies. With affiliates in Nerviano (Italy), Boston (USA), and Shanghai (China), NMS leverages deep expertise in drug discovery and translational medicine to advance a pipeline of novel candidates from bench to bedside.

Forward-Looking Statement

This press release contains forward-looking statements regarding future events and the development of atamparib, including anticipated trial commencement, clinical strategies, and potential patient benefits. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. NMS undertakes no obligation to publicly update any forward-looking statement.

[1]Manetsch P, Hottiger MO. Unleashing viral mimicry: A combinatorial strategy to enhance the efficacy of PARP7 inhibitors. Bioessays. 2025 Feb;47(2):e2400087. doi: 10.1002/bies.202400087. Epub 2024 Nov 6. PMID: 39502005; PMCID: PMC11755700.

For more information, visit https://www.nervianoms.com

Media Relations: mediarelations@nervianoms.com